Aspire Biopharma shares surge 41.78% intraday after CDMO agreement with Microsize to develop sublingual aspirin candidate.

Aspire Biopharma Holdings, Inc. (ASBP) surged 41.78% intraday following announcements of a strategic collaboration with Microsize, a North American CDMO, to develop its 162 mg sublingual aspirin powder for emergency treatment of suspected acute myocardial infarction. The partnership, highlighted in two press releases, underscores progress toward a 2026 Section 505(b)(2) New Drug Application and an upcoming clinical trial evaluating the drug’s efficacy in 32 healthy volunteers. The agreement aligns with Aspire’s focus on optimizing existing therapeutics for faster onset and reduced side effects, while leveraging Microsize’s expertise in particle engineering. Interim CEO Kraig Higginson emphasized the milestone as critical to advancing U.S.-based innovation and regulatory submissions, reinforcing investor confidence in the company’s pipeline. The sharp intraday rally reflects optimism over the partnership’s potential to accelerate commercialization and validate the sublingual aspirin’s therapeutic value.